Affinage

CBLN2

Cerebellin-2 · UniProt Q8IUK8

Length
224 aa
Mass
24.1 kDa
Annotated
2026-06-09
52 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CBLN2 is a secreted N-linked glycoprotein of the cerebellin family that functions as a trans-synaptic organizer, bridging presynaptic neurexins to postsynaptic delta-type glutamate receptors to maintain synapses and tune receptor signaling (PMID:17331201, PMID:29784783). It forms homomeric and heteromeric complexes with other cerebellins (CBLN1, CBLN3, CBLN4), and heteromer formation modulates secretion and receptor affinity (PMID:17331201, PMID:22220752). CBLN2 binds selectively to α- and β-neurexins carrying the splice site 4 insert [NRXs(S4+)] in a Ca2+-independent manner and simultaneously to postsynaptic GluD1/GluD2 (GluRδ1/δ2), assembling a tripartite neurexin–CBLN2–GluD complex; through this complex it induces presynaptic differentiation in cultured cerebellar, hippocampal, and cortical neurons, with a preference for inhibitory differentiation relative to neuroligin 1 (PMID:21410790, PMID:22191730, PMID:21356198, PMID:29784783). In vivo, CBLN2 is required not for initial synaptogenesis but for long-term synapse maintenance and circuit-specific control of glutamate receptor responses: at CA1→subiculum and prefrontal synapses, Nrxn1SS4+–CBLN2 signaling enhances NMDA-receptor responses while Nrxn3SS4+–CBLN2 signaling suppresses AMPA-receptor responses, and Cbln1/2 loss reduces hippocampal excitatory synapse density in aging mice and produces salience-induced seizures (PMID:29691328, PMID:36205393). It shows partial functional redundancy with CBLN1 in cerebellum yet non-redundant roles in other circuits (PMID:22117778). In the dorsal raphe, CBLN2 regulates serotonergic circuits, and its loss produces compulsive behaviors reversible by recombinant CBLN2 or serotonergic drugs (PMID:34158618). CBLN2 transcription is controlled by retinoic-acid signaling through a RARα-bound promoter and a Hominini-specific enhancer subject to SOX5 regulation that drives prefrontal dendritic spine formation (PMID:34599306, PMID:37247722). Beyond the nervous system, CBLN2 acts in disease contexts: it is induced in sensory ganglia via SOX11-driven transcription and TET3-mediated promoter demethylation to drive neuropathic pain through NF-κB and ERK signaling (PMID:41162740, PMID:40665237), promotes pulmonary endothelial–mesenchymal transition via NF-κB/HIF-1α/Twist1 (PMID:37355224), and suppresses oncogenic STAT3/PD-L1/β-catenin signaling in colorectal cancer (PMID:39577217).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 1994 High

    Established CBLN2 as a gene distinct from CBLN1, defining the molecular identity that all subsequent functional work would build upon.

    Evidence Molecular cloning, sequence alignment, Southern blot, and genetic mapping in mouse

    PMID:7877445

    Open questions at the time
    • No functional role assigned at cloning
    • Protein product and secretion not characterized
  2. 2007 High

    Showed CBLN2 is a secreted glycoprotein capable of homo- and heteromeric assembly with other cerebellins, defining it as a secreted oligomeric signaling molecule rather than a cell-intrinsic factor.

    Evidence Heterologous cell transfection, Western blot, immunoprecipitation, and secretion assay

    PMID:17331201

    Open questions at the time
    • Receptors and synaptic targets not yet identified
    • Stoichiometry of native complexes not resolved
  3. 2011 High

    Identified the dual receptor system — presynaptic NRXs(S4+) and postsynaptic GluRδ1/δ2 — establishing CBLN2 as a bidirectional synaptic bridge that competes with neuroligin-mediated synaptogenesis.

    Evidence In vitro and co-culture synaptogenesis assays, pulldown binding, surface plasmon resonance, and Ca2+-sensitivity testing in cultured neurons

    PMID:21356198 PMID:21410790 PMID:22191730

    Open questions at the time
    • In vivo relevance of in vitro synaptogenesis unestablished
    • Preference for inhibitory vs excitatory differentiation mechanism unclear
  4. 2012 High

    Defined CBLN2's place within the cerebellin family by demonstrating shared GluRδ2/neurexin binding and functional redundancy with CBLN1 in cerebellum but non-redundant roles elsewhere, and distinguished it from the DCC-binding CBLN4.

    Evidence Transgenic rescue of Cbln1-null Purkinje cells, Cbln2 knockout mice, receptor binding and displacement assays

    PMID:22117778 PMID:22220752

    Open questions at the time
    • Circuit basis of non-redundant thalamic role not defined
    • CBLN4-receptor finding is Medium-confidence single-lab
  5. 2018 High

    Reframed CBLN2 from a synaptogenic factor to a maintenance factor by showing it assembles a tripartite NRX1β(S4+)–CBLN2–GluD1 complex required for long-term hippocampal synapse maintenance, not initial formation.

    Evidence Cbln2 single, double, and triple KO mice, electrophysiology, synapse density quantification, and seizure/behavioral phenotyping

    PMID:29691328 PMID:29784783

    Open questions at the time
    • Molecular mechanism distinguishing maintenance from formation unresolved
    • Why deficits manifest in aging not explained
  6. 2021 High

    Linked CBLN2 to a behavioral circuit by showing it regulates dorsal raphe serotonergic function, with loss causing compulsive behavior reversible by recombinant protein and serotonergic drugs.

    Evidence Constitutive and conditional KO mice, behavioral assays, HPLC serotonin measurement, recombinant protein and pharmacological rescue

    PMID:34158618

    Open questions at the time
    • Synaptic substrate within raphe circuits not identified
    • Connection between serotonin loss and synaptic role unclear
  7. 2021 High

    Established RARα/retinoic-acid and a Hominini-specific SOX5-regulated enhancer as transcriptional drivers of CBLN2 controlling prefrontal expression and dendritic spine formation, providing an evolutionary and regulatory dimension.

    Evidence Comparative transcriptomics, enhancer/ChIP analysis, in situ genetic humanization of the mouse enhancer, dendritic spine quantification, and RA supplementation with RARα ChIP in a VPA autism model

    PMID:34599306 PMID:37247722

    Open questions at the time
    • Direct link from enhancer-driven expression to specific synaptic outputs incomplete
    • VPA-model RARα axis is Medium-confidence single lab
  8. 2022 High

    Dissected circuit-specific receptor signaling, showing distinct neurexin splice isoforms route through CBLN2–GluD1 to oppositely modulate NMDA vs AMPA receptor responses without changing synapse number.

    Evidence Constitutive Cbln2 deletion, circuit-specific electrophysiology of AMPA/NMDA responses, spine/synapse density quantification across brain regions

    PMID:36205393

    Open questions at the time
    • Downstream signaling from GluD1 to receptor modulation not defined
    • How a single ligand produces opposite outputs is unresolved
  9. 2024 Medium

    Provided a disease-relevant structural anchor by showing a GRID1/GluD1 amino-terminal variant disrupts GluD1–CBLN2 complex formation, implicating the interaction in synaptopathology.

    Evidence Site-directed mutagenesis and biochemical co-complex assay

    PMID:37944084

    Open questions at the time
    • Single biochemical assay without in vivo synaptic readout
    • Disease causality not established
  10. 2025 Medium

    Extended CBLN2 beyond synaptic maintenance into pathological signaling by showing transcriptional/epigenetic induction (SOX11, TET3 demethylation) drives neuropathic pain through NF-κB and ERK, and that CBLN2 acts in non-neural disease via NF-κB/HIF-1α/Twist1 in pulmonary endothelium and STAT3/PD-L1/β-catenin in colorectal cancer.

    Evidence ChIP, methylation assays, in vivo siRNA knockdown, exogenous protein and pathway inhibitors with behavioral, electrophysiological, and tumor readouts; plus overexpression/EndMT cell and animal models

    PMID:29705514 PMID:37355224 PMID:39577217 PMID:40665237 PMID:41162740

    Open questions at the time
    • Receptor mediating pro-inflammatory/EndMT signaling not identified
    • Relationship between synaptic NRX/GluD function and non-neural signaling unknown
    • All single-lab findings

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CBLN2–GluD1 engagement transduces opposite, circuit-specific modulation of AMPA versus NMDA receptors and what receptor mediates its non-synaptic NF-κB/ERK/HIF-1α actions remain unresolved.
  • No downstream signaling mechanism from GluD1 defined
  • No receptor identified for peripheral/disease signaling
  • No structural model of the native tripartite complex

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098631 cell adhesion mediator activity 3 GO:0048018 receptor ligand activity 2 GO:0060089 molecular transducer activity 2
Localization
GO:0005576 extracellular region 2
Pathway
R-HSA-112316 Neuronal System 2 R-HSA-1500931 Cell-Cell communication 2 R-HSA-1266738 Developmental Biology 1
Partners
CBLN1CBLN4GRID1GRID2NRXN1NRXN3RARASOX5
Complex memberships
neurexin(S4+)–CBLN2–GluD1 tripartite trans-synaptic complex

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 CBLN2 (like CBLN1) specifically binds to α and β isoforms of neurexin carrying the splice site 4 insert [NRXs(S4+)] and induces synaptogenesis in cerebellar, hippocampal, and cortical neurons in vitro. CBLN1 and CBLN2 compete with neuroligin 1-mediated synaptogenesis by sharing presynaptic receptor NRXs(S4+). The CBLN2–NRX interaction is insensitive to extracellular Ca2+ concentrations. In vitro synaptogenesis assay, binding competition assay, Ca2+-sensitivity assay The European journal of neuroscience High 21410790
2011 CBLN2 binds to the N-terminal domain of GluRδ1 and induces preferentially inhibitory presynaptic differentiation of cultured cortical neurons when added together with GluRδ1-expressing HEK293T cells. The synaptogenic activity of CBLN2 is suppressed by soluble extracellular domain of NRXN1α or NRXN1β(S4), indicating CBLN2 bridges GluRδ1 postsynaptically and NRXNs presynaptically. Co-culture synaptogenesis assay, direct binding assay (pulldown), HEK293T cell transfection Journal of neurochemistry High 21356198 22191730
2011 CBLN1 and CBLN2 show robust binding to NRXN1α and all three β-NRXNs, selective for variants containing splice segment 4 (S4). CBLN2 has lower binding affinity to NRXNs than CBLN1 as measured by surface plasmon resonance. CBLN4 shows much weaker interaction with NRXNs. CBLN2 induces presynaptic differentiation of cortical neurons, with preferentially inhibitory over excitatory presynaptic differentiation compared to neuroligin 1. Surface plasmon resonance binding assay, in vitro synaptogenesis assay with cultured cortical neurons Biochemical and biophysical research communications High 21356198
2007 CBLN2 is secreted as an N-linked glycoprotein from mammalian heterologous cells. CBLN2 forms not only homomeric but also heteromeric complexes with other Cbln family members (including CBLN1, CBLN3, CBLN4) in vitro. Heteromer formation can modulate secretion and trafficking of family members. Transfection of heterologous cells, Western blot, immunoprecipitation, secretion assay The European journal of neuroscience High 17331201
2012 CBLN1 and CBLN2 both bind to GluRδ2 and NRXN1-3; ectopic expression of CBLN2 in Purkinje cells of Cbln1-null mice rescues cerebellar synaptic deficits, demonstrating functional redundancy with CBLN1 in the cerebellum mediated through shared receptor binding. However, Cbln2-null mice do not display the striatal synaptic alterations seen in Cbln1-null mice, indicating non-redundant roles in thalamic neurons. Transgenic rescue (ectopic Cbln2 expression in Purkinje cells of Cbln1-null mice), Cbln2 knockout mouse generation, binding assays, synaptic morphology analysis Journal of neurochemistry High 22117778
2012 CBLN4, but not CBLN1 or CBLN2, selectively binds the netrin receptor DCC in a netrin-displaceable fashion. CBLN1 and CBLN2 both bind GluRδ2 and neurexins 1–3, whereas CBLN4 binds weakly or not at all. Heteromeric complexes of CBLN1+CBLN4 have greatly reduced affinity for DCC but increased affinity for neurexins. Candidate receptor-screening binding assay, netrin displacement assay, co-immunoprecipitation Journal of neurochemistry Medium 22220752
2018 GluD1 (δ1 glutamate receptor) requires CBLN2 to assemble and maintain excitatory synapses in the hippocampus. The action of GluD1 is absent in Cbln2 knockout mice. GluD1 actions further require presynaptic neurexin 1β carrying the splice site 4 insert (+S4). Together, CBLN2 forms a tripartite complex linking presynaptic neurexin 1β(+S4) to postsynaptic GluD1 for hippocampal synapse assembly and maintenance. Cbln2 knockout mice, electrophysiology, synapse density analysis, genetic epistasis with neurexin splice variants Proceedings of the National Academy of Sciences of the United States of America High 29784783
2018 Cbln1/2 double-KO (but not single KO) mice exhibit salience-induced seizures, and a selective ~50% decrease in hippocampal excitatory synapse density in the stratum lacunosum moleculare and dentate gyrus of aging (6-month-old) mice, as well as decreased synapse density in striatum and retrosplenial cortex. Cerebellins do not contribute to initial synapse formation but are required for long-term synapse maintenance. Constitutive single, double, and triple KO mice; synapse density quantification; behavioral testing (seizure assessment, motor behavior) The Journal of neuroscience High 29691328
2021 Constitutive Cbln2 KO mice display robust compulsive behaviors (stereotypic pattern running, marble burying, explosive jumping, excessive nest building) and decreased brain serotonin levels. Conditional deletion of Cbln2 from dorsal raphe neurons or from presynaptic neurons synapsing onto dorsal raphe neurons reproduces compulsive behaviors. Injection of recombinant CBLN2 protein into the dorsal raphe of Cbln2 KO mice largely reverses compulsive behaviors. Serotonin precursor 5-HTP or fluoxetine alleviated compulsive behaviors in Cbln2 KO mice. Constitutive and conditional KO mice, behavioral assays, HPLC serotonin measurement, recombinant protein injection rescue, pharmacological rescue Molecular psychiatry High 34158618
2022 At CA1→subiculum synapses, Nrxn1SS4+ and Nrxn3SS4+ act through secreted CBLN2 to activate postsynaptic GluD1: Nrxn1SS4+–CBLN2 signaling enhances NMDA-receptor responses, while Nrxn3SS4+–CBLN2 signaling suppresses AMPA-receptor responses, without affecting synapse formation or number. In the prefrontal cortex, Nrxn1SS4+–CBLN2 signaling selectively controls NMDA-receptors without affecting spine or synapse numbers. Constitutive Cbln2 deletion confirms these functions with no additional developmental synaptogenic role. Constitutive Cbln2 deletion in mice, electrophysiology (AMPA/NMDA receptor recordings), spine/synapse density quantification in multiple brain regions eLife High 36205393
2021 Species differences in CBLN2 expression level and laminar distribution in the prefrontal cortex are, at least in part, due to Hominini-specific deletions containing SOX5-binding sites within a retinoic acid-responsive CBLN2 enhancer. In situ genetic humanization of the mouse Cbln2 enhancer drives increased and ectopic laminar Cbln2 expression and promotes prefrontal cortex dendritic spine formation. Comparative transcriptomics, enhancer analysis, ChIP for SOX5-binding sites, in situ genetic humanization of mouse Cbln2 enhancer, dendritic spine quantification Nature High 34599306
2024 A GRID1 variant in the distal amino-terminal domain at a position predicted to interact with CBLN2/CBLN4 disrupts complex formation between GluD1 and CBLN2, as demonstrated by biochemical assay, potentially perturbing synapse organization. Site-directed mutagenesis of GluD1 variant, biochemical co-complex assay Human molecular genetics Medium 37944084
2023 CBLN2 promotes endothelial-mesenchymal transition (EndMT) in hypoxic pulmonary hypertension by activating the NF-κB/HIF-1α/Twist1 pathway. CBLN2 siRNA, NF-κB inhibitor PDTC, and HIF-1α inhibitor KC7F2 each inhibit hypoxia-induced EndMT in HPAECs. Hypoxia-induced PH rat model, EndMT cell model, siRNA knockdown, pathway inhibitors, Western blot, immunofluorescence Life sciences Medium 37355224
2023 Retinoic acid (RA) supplementation increases RARα expression and enhances RARα binding to CBLN2 promoters (confirmed by ChIP assay), upregulating CBLN2 expression in the cerebellum of VPA-treated autistic rats and ameliorating motor coordination deficits. This establishes a RARα→CBLN2 transcriptional regulatory axis. VPA rat autism model, RA supplementation, ChIP assay for RARα at Cbln2 promoter, qPCR, behavioral motor assays Neuroscience letters Medium 37247722
2025 SOX11 binds to 12 cis-regulatory elements within the Cbln2 promoter to enhance its transcription following spinal nerve ligation (SNL). CBLN2 expression is persistently upregulated in dorsal root ganglia after SNL. siRNA knockdown of Sox11 or Cbln2 attenuates SNL-induced mechanical allodynia and thermal hyperalgesia. Exogenous CBLN2 activates NF-κB signaling and induces neuronal hyperexcitability; inhibition of NF-κB reduces CBLN2-induced pain hypersensitivity and proinflammatory cytokine production. ChIP assay (SOX11 at Cbln2 promoter), siRNA knockdown in vivo, intrathecal CBLN2 injection, high-throughput sequencing, NF-κB inhibitor pharmacology, behavioral pain assays Neuroscience bulletin Medium 41162740
2025 TET3-mediated demethylation of the Cbln2 promoter drives CBLN2 upregulation in the trigeminal ganglion following partial infraorbital nerve transection (pIONT). Tet3 knockdown alleviates neuropathic pain and downregulates Cbln2. Exogenous CBLN2 potentiates neuronal excitability and activates ERK signaling; inhibition of the MEK/ERK pathway abolishes CBLN2-induced hypersensitivity and suppresses proinflammatory cytokine expression. Methylation-specific PCR, bisulfite sequencing PCR, siRNA knockdown in vivo, whole-cell patch-clamp, ERK pathway inhibitors, behavioral pain assays The journal of headache and pain Medium 40665237
2018 CBLN2-derived peptides (3 novel peptides identified by mass spectrometry from dorsal horn spinal cord) induce mechanical hypersensitivity upon intrathecal injection in mice. Two of three CBLN2-derived peptides significantly increased pain responses in the first 6 hours post-injection compared to saline controls. Mass spectrometry peptide identification from spinal cord, intrathecal injection, von Frey mechanical sensitivity testing Neuropeptides Medium 29705514
2024 CBLN2 overexpression inhibits STAT3-induced PD-L1 and beta-catenin activation in colorectal cancer cells and inhibits oncogenic properties in vitro and tumor growth in vivo. CBLN2 overexpression improves immune checkpoint blockade efficacy in the MC38 CRC model. Overexpression in CRC cell lines, in vivo tumor growth assay, Western blot for STAT3/PD-L1/beta-catenin, MC38 syngeneic tumor model with ICB treatment International immunopharmacology Medium 39577217
1994 CBLN2 was cloned as a distinct gene from CBLN1; amino acid comparison revealed CBLN2 is 88% identical to the carboxy-terminal region of CBLN1. Southern analysis confirmed they are independent genes. Cbln2 maps to the distal end of mouse chromosome 18. Molecular cloning, sequence alignment, Southern blot, genetic mapping Brain research. Molecular brain research High 7877445

Source papers

Stage 0 corpus · 52 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Cbln family proteins promote synapse formation by regulating distinct neurexin signaling pathways in various brain regions. The European journal of neuroscience 134 21410790
2006 Distinct expression of Cbln family mRNAs in developing and adult mouse brains. The European journal of neuroscience 92 16930405
2013 Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nature genetics 89 23502781
2012 Pathogenetic model for Tourette syndrome delineates overlap with related neurodevelopmental disorders including Autism. Translational psychiatry 89 22948383
2021 Hominini-specific regulation of CBLN2 increases prefrontal spinogenesis. Nature 64 34599306
2008 Cbln and C1q family proteins: new transneuronal cytokines. Cellular and molecular life sciences : CMLS 64 18278437
2014 The genetic basis of pulmonary arterial hypertension. Human genetics 60 24442418
2018 Genetic Ablation of All Cerebellins Reveals Synapse Organizer Functions in Multiple Regions Throughout the Brain. The Journal of neuroscience : the official journal of the Society for Neuroscience 59 29691328
2013 GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 59 23651021
2012 Glutamate receptor δ1 induces preferentially inhibitory presynaptic differentiation of cortical neurons by interacting with neurexins through cerebellin precursor protein subtypes. Journal of neurochemistry 58 22191730
2017 Cerebellins are differentially expressed in selective subsets of neurons throughout the brain. The Journal of comparative neurology 56 28714144
2012 The Cbln family of proteins interact with multiple signaling pathways. Journal of neurochemistry 52 22220752
2018 Postsynaptic δ1 glutamate receptor assembles and maintains hippocampal synapses via Cbln2 and neurexin. Proceedings of the National Academy of Sciences of the United States of America 49 29784783
2007 Characterization of a transneuronal cytokine family Cbln--regulation of secretion by heteromeric assembly. The European journal of neuroscience 47 17331201
2011 Differential interactions of cerebellin precursor protein (Cbln) subtypes and neurexin variants for synapse formation of cortical neurons. Biochemical and biophysical research communications 46 21356198
2021 Transcriptomic encoding of sensorimotor transformation in the midbrain. eLife 45 34318750
2021 A brain-to-spinal sensorimotor loop for repetitive self-grooming. Neuron 33 34932943
2007 Mapping of Cbln1-like immunoreactivity in adult and developing mouse brain and its localization to the endolysosomal compartment of neurons. The European journal of neuroscience 31 18001291
2012 Comparison of Cbln1 and Cbln2 functions using transgenic and knockout mice. Journal of neurochemistry 30 22117778
2013 Genetics and the molecular pathogenesis of pulmonary arterial hypertension. Current hypertension reports 29 24078385
2022 Distinct neurexin-cerebellin complexes control AMPA- and NMDA-receptor responses in a circuit-dependent manner. eLife 27 36205393
2021 Cerebellin-2 regulates a serotonergic dorsal raphe circuit that controls compulsive behaviors. Molecular psychiatry 24 34158618
2021 Dysfunction of Glutamate Delta-1 Receptor-Cerebellin 1 Trans-Synaptic Signaling in the Central Amygdala in Chronic Pain. Cells 24 34685624
2023 Sex-specific genetic architecture of late-life memory performance. Alzheimer's & dementia : the journal of the Alzheimer's Association 23 37984853
1994 Genomic structure and mapping of precerebellin and a precerebellin-related gene. Brain research. Molecular brain research 22 7877445
2016 High Frequency of Pulmonary Hypertension-Causing Gene Mutation in Chinese Patients with Chronic Thromboembolic Pulmonary Hypertension. PloS one 21 26820968
2023 Cerebellin-2 promotes endothelial-mesenchymal transition in hypoxic pulmonary hypertension rats by activating NF-κB/HIF-1α/Twist1 pathway. Life sciences 19 37355224
2015 A New Genomewide Association Meta-Analysis of Alcohol Dependence. Alcoholism, clinical and experimental research 19 26173551
2011 Localization of cerebellin-2 in late embryonic chicken brain: implications for a role in synapse formation and for brain evolution. The Journal of comparative neurology 19 21456003
2008 Expression of precerebellins in cultured rat calvaria osteoblast-like cells. International journal of molecular medicine 16 18813864
2009 Precerebellin-related genes and precerebellin 1 peptide in endocrine glands of the rat - pattern of their expression. International journal of molecular medicine 14 19082514
2024 Clinical features, functional consequences, and rescue pharmacology of missense GRID1 and GRID2 human variants. Human molecular genetics 13 37944084
2021 Development and validation of a risk prediction model and nomogram for colon adenocarcinoma based on methylation-driven genes. Aging 12 34182539
2021 A high plane of nutrition during early life alters the hypothalamic transcriptome of heifer calves. Scientific reports 11 34234169
2018 Spinal injection of newly identified cerebellin-1 and cerebellin-2 peptides induce mechanical hypersensitivity in mice. Neuropeptides 11 29705514
2023 Retinoic acid supplementation ameliorates motor incoordination via RARα-CBLN2 in the cerebellum of a prenatal valproic acid-exposed rat autism model. Neuroscience letters 9 37247722
2014 Parcellation of cerebellins 1, 2, and 4 among different subpopulations of dorsal horn neurons in mouse spinal cord. The Journal of comparative neurology 9 23853053
2010 Identification of cerebellin2 in chick and its preferential expression by subsets of developing sensory neurons and their targets in the dorsal horn. The Journal of comparative neurology 9 20506477
2009 Precerebellin-related genes and precerebellin 1 peptide in the adrenal gland of the rat: expression pattern, localization, developmental regulation and effects on corticosteroidogenesis. International journal of molecular medicine 7 19212655
2023 Effects of Mitochondrial Transplantation on Transcriptomics in a Polymicrobial Sepsis Model. International journal of molecular sciences 5 37895006
2025 Cell-death pathways and tau-associated neuronal vulnerability in Alzheimer's disease. Cell reports 3 40448997
2025 SOX11-mediated CBLN2 Upregulation Contributes to Neuropathic Pain through NF-κB-Driven Neuroinflammation in Dorsal Root Ganglia of Mice. Neuroscience bulletin 3 41162740
2024 A systematic approach introduced some immune system targets in rectal cancer by considering cell-free DNA methylation in response to radiochemotherapy. Cytokine 2 38906038
2025 Histone H3 lysine 9 tri-methylation is associated with pterygium. BMC ophthalmology 1 40033254
2025 Promoter demethylation of cerebellin 2 by ten-eleven translocation 3 contributes to peripheral sensitization in trigeminal neuropathic pain of mice. The journal of headache and pain 1 40665237
2024 CBLN2 overexpression inhibits colorectal cancer progression and improves immunotherapy responses. International immunopharmacology 1 39577217
2026 CBLN2 promoter enables genetic access to wide-field neurons of the tree shrew superior colliculus. Cell reports methods 0 41794023
2026 Structural Architecture and Evolutionary Conservation of Cerebellin-Mediated Trans-Synaptic Signaling. Synapse (New York, N.Y.) 0 41995212
2026 Excitatory neurons and astrocytes-specific dysregulation and aberrant interactions are vulnerable to FCDI as suggested by single-cell spatial transcriptomics. Clinical and translational medicine 0 42068085
2026 Expression of sulfate pathway genes in human neurodevelopment. Journal of neurogenetics 0 42101182
2025 Granulosa-cumulus cells global transcriptome sequencing as a predictor of embryo development: a preliminary study. Minerva obstetrics and gynecology 0 40736440
2025 Mouse Gnal transcripts and transcriptomics in isolated dystonia. Research square 0 40909808

Missed literature

Know a paper Affinage missed for CBLN2? Flag it for the maintainers and the community.

No submissions yet.